Data as of 11:27am ET
| +0.02 / +0.25%|
Imprimis Pharmaceuticals, Inc. is a pharmaceutical company. The company is engaged in the development of non-invasive, topically delivered products. Its innovative patented Accudel cream formulation technology is designed to enable highly targeted site specific treatment. The company's pain product candidate utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. It intends to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications. Imprimis Pharmaceuticals was founded in January 2006 and is headquartered in Solana Beach, CA.
|Mark L. Baum||Chief Executive Officer, Secretary & Director|
|Joachim P. H. Schupp||Chief Medical Officer|
|John Saharek||Vice President-Ophthalmology Commercialization|
|Andrew R. Boll||Vice President-Accounting & Public Reporting|